Alamar Biosciences began trading on Nasdaq after pricing its initial public offering of 12.94 million shares at $17 each, raising gross proceeds of about $220 million for its Argo HT platform and assay expansion plans. The company plans to develop a clinical version of Argo HT, targeting an FDA 510(k) submission next year, and will use proceeds to grow commercial infrastructure and add assay content across oncology, cardiology, metabolic disease, and health monitoring. Alamar’s NULISA-based immunoassay arrays can support panels of up to 220 assays, and the company said it intends the clinical instrument to operate in both research-use and diagnostic modes depending on customer workflow. The initial IPO milestone adds momentum to the proteomics and high-sensitivity immunoassay tool market, where translational bridge products and regulatory-cleared instruments are increasingly key differentiators.